June 2015

The array of services and opportunities with which Florida Cancer Specialists & Research Institute provides its physicians, while still allowing them a high degree of autonomy, has proved a powerful draw since the group was founded as a solo practice by William Harwin, MD, in 1984.

The road to becoming the first biosimilar to go on sale in the United States has been uneven for Zarxio (filgrastim-sndz), a Sandoz product for raising white blood cell counts.

PracticeNET is an initiative emerging from ASCO's Clinical Affairs Department designed to help practices learn from one another's successes as they move farther away from fee-for-service and toward increasingly cost-effective models of care.

The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs, but payment systems for covering and reimbursing for these tests have fallen behind the times.

The rising number of oral oncology drugs that can be supplied through pharmacy networks rather than administered in clinical settings, such as intravenous drugs, has many physicians worried that they are losing control of an important part of the therapeutic process.

The FDA's approval in March of the first biosimilar drug for the US market has aroused much concern among physicians.